Cassopeia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-12-2024
- Paid Up Capital ₹ 0.10 M
as on 31-12-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
About Cassopeia Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Yad Ram and Bijender Singh serve as directors at the Company.
- CIN/LLPIN
U24304HR2020PTC086955
- Company No.
086955
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cassopeia Pharmaceuticals Private Limited offer?
Cassopeia Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Gastrointestinal Drugs, Common Disease Medicines, Pharmaceutical Medicine, Antihistamines, Cough Syrup, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Anti Ulcer Drugs.
Who are the key members and board of directors at Cassopeia Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yad Ram  | Director | 23-Jun-2020 | Current |
| Bijender Singh | Director | 13-Oct-2021 | Current |
Financial Performance of Cassopeia Pharmaceuticals.
Cassopeia Pharmaceuticals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Cassopeia Pharmaceuticals?
In 2021, Cassopeia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cassopeia Pharmaceuticals?
Cassopeia Pharmaceuticals has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cassopeia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cassopeia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
